meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
Amantadine
ASC09/ritonavir
azithromycin
azvudine
baloxavir marboxil
bromhexine
carrimycin
chloroquine and derivatives
danoprevir / ritonavir
darunavir cobicistat
doxycycline
Emtricitabine/tenofovir plus colchicine plus rosuvastatin
Ensitrelvir (XOCOVA)
favipiravir
favipiravir plus interferon
fluvoxamine
hydroxychloroquine plus macrolides
Interferon plus lopinavir/ritonavir
ivermectin
leronlimab
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir
lopinavir/ritonavir plus chloroquine
Lopinavir/ritonavir plus hydroxychloroquine
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b
molnupiravir
niclosamide
nirmatrelvir / ritonavir (Paxlovid)
nitazoxanide
opaganib
oseltamivir
oseltamivir plus chloroquin
remdesivir
ribavirin
ritonavir
sofosbuvir
sofosbuvir and daclatasvir
sofosbuvir and ledipasvir
tenofovir/emtricitabine
tenofovir/emtricitabine plus hydroxychloroquine
tranexamic acid
tranilast
triazavirin
umifenovir (arbidol)
zinc
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
potential COVID-19 treatments
antiviral and associated therapy
lopinavir/ritonavir
control
standard of care
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded